Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | FLT1 | P17948 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
| ▸ | TEK | Q02763 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15114825 | 0.86 | MEN1 (0.60) | MEN1KMT2AKDM4EFLT1KDR | |
| SCHEMBL9744026 | 0.80 | MAPT (0.58) | MEN1KMT2AKDM4EFLT1KDR | |
| SCHEMBL11403139 | 0.78 | MAPK14 (0.63) | MEN1KMT2AKDM4EFLT1KDR | |
| SCHEMBL12991482 | 0.77 | MEN1 (0.58) | MEN1KMT2AKDM4EFLT1KDR | |
| SCHEMBL9743602 | 0.77 | MAPT (0.58) | MEN1KMT2AKDM4EFLT1KDR | |
| SCHEMBL4764648 | 0.74 | TEK (1.00) | MEN1KMT2AKDM4EFLT1KDR | |
| SCHEMBL4764646 | 0.74 | TEK (1.00) | MEN1KMT2AKDM4EFLT1KDR | |
| SCHEMBL18884070 | 0.73 | MEN1 (0.54) | MEN1KMT2AKDM4EFLT1KDR | |
| SCHEMBL20078217 | 0.73 | ALDH1A1 (0.54) | MEN1KMT2AKDM4EFLT1KDR | |
| SCHEMBL18878417 | 0.73 | MAPT (0.54) | MEN1KMT2AKDM4EFLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9846160-B2 | Ganglioside GD2 as a marker and target on cancer stem cells | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2017-12-19 | — | — | US | disclosed |
| US-9846160-B2 | Ganglioside GD2 as a marker and target on cancer stem cells | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2017-12-19 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-09-26 | — | — | US | disclosed |
| WO-2013130603-A1 | GANGLIOSIDE GD2 AS A MARKER AND TARGET ON CANCER STEM CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | DANA-FARBER CANCER INSTITUTE, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-07-18 | — | — | US | disclosed |
| EP-1575963-B1 | ANTI-ANGIOGENETIC THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-20060069109-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
| EP-1575963-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058776-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | MEN1 4108/4885KMT2A 415/4885KDM4E 1552/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | MEN1 1913/4885KMT2A 134/4885KDM4E 317/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | MEN1 2413/4885KMT2A 231/4885KDM4E 1909/4885 |
| US-20130210813-A1 | Male Contraceptive Compositions and Methods of Use | SHBG, CYP19A1, CYP17A1 | MEN1 389/4885KMT2A 2696/4885KDM4E 903/4885 |
| US-20060069109-A1 | Therapeutic agents | TIE1, TEK, KDR | MEN1 242/4885KMT2A 1034/4885KDM4E 2006/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | MEN1 4108/4885KMT2A 415/4885KDM4E 1552/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | MEN1 2413/4885KMT2A 231/4885KDM4E 1909/4885 |
| US-20130184264-A1 | Compositions And Methods For Treating Neoplasia, Inflammatory Disease And Other Disorders | BRPF3, EP300, BRD3 | MEN1 1913/4885KMT2A 134/4885KDM4E 317/4885 |
| US-20130252331-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLISM | BRD3, BRD2, BRD4 | MEN1 4189/4885KMT2A 599/4885KDM4E 1108/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | MEN1 1913/4885KMT2A 134/4885KDM4E 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.